Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Ambani-backed robot startup seeks $100 million to take on China
Reliance-backed robotics startup Addverb Technologies is looking to raise over $100 million to fund expansion into humanoid robots, AI and advanced automation. The company, which generates half its revenue overseas, targets a spot among the world's top 10 robotics firms within five years.

Glenmark Pharma Profit Expected To Soar 5x in Two Years, Says Motilal Oswal — Check Target Price
Glenmark Pharma's shares are likely to remain in focus after Motilal Oswal has reiterated its positive stance on the stock.

ICICI Lombard: AI Integration Lifts Growth Outlook — Buy, Sell or Hold? Read Motilal Oswal's Analysis
Leadership in motor insurance, accelerating momentum in retail health, expanding distribution capabilities, growing AI integration and a strong balance sheet remains ICICI Lombard's key growth drivers.
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stake
Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per share. Despite this divestment, analysts remain positive on Emcure's growth outlook across its core therapeutic segments.
Sebi may widen 50% overlap rule to thematic passive mutual fund schemes
Curb on number of smart-beta schemes also likely; move aimed at curbing proliferation in segment

Ajanta Pharma promoter sells ₹1,024 crore stake; mutual funds step in as buyers
A promoter entity of Ajanta Pharma has sold a 2.8% stake in the drugmaker for over ₹1,000 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund emerging as the key buyers.
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.

Dr. Agarwal's Shares May Rally 35% on Strong Surgical Growth, Says Motilal Oswal — Check Target Price
Motilal Oswal remains bullish on Dr. Agarwal's structural growth story, backed by its leadership in the eye-care segment and a rapidly scaling surgical franchise.

Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends 3 stocks to buy today amid RBI policy - 5 June 2026
Shares to buy or sell: Chandan Taparia has recommended three stocks to buy today, 5 June 2026 - BSE, Laurus Labs and Exide Industries shares.

Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 2 June 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 2 June 2026Mint
Blue Jet Healthcare gains 8% post Q4; analysts split on near-term prospects
Emkay Global has retained its 'Reduce' rating, while Motilal Oswal has maintained its 'Buy' stance, reflecting contrasting expectations on recovery in key business segments and the margin trajectory

Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 26 May 2026 - Mint
Shares to buy or sell: Chandan Taparia of Motilal Oswal recommends three stocks to buy today - 26 May 2026Mint